Vsetin 1

Researchers are evaluating the safety and effectiveness of LY4268989 compared to a placebo in adults with moderately to severely active ulcerative colitis UC. The study focuses on participants with a diagnosis of UC for at least 3 months, confirmed by specific clinical and endoscopic criteria. This Phase 2 trial aims to better understand how LY4268989 may impact clinical remission and response in this patient group over a long-term period. Participants will receive either one of two doses of LY4268989 or a placebo, all administered orally. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period lasts up to approximately 108 weeks, excluding the screening phase, allowing for assessment of the drug over an extended time. During the study, participants will undergo regular evaluations including clinical assessments using the Modified Mayo Score to measure remission and response at multiple time points, including weeks 10 and 52. Researchers will also monitor symptomatic response and measure plasma concentrations of LY4268989. Safety and effectiveness will be tracked through these clinical and laboratory tests to understand the drugs impact on UC over the study duration.

Researchers are investigating the link between preoperative cognitive impairment and postoperative delirium POD in adults aged 65 and older undergoing elective total hip arthroplasty in the Czech Republic. Postoperative delirium is a common and serious complication associated with higher risks of illness, death, longer hospital stays, and lasting cognitive and functional decline. Despite recommendations, regular cognitive screening before surgery is not widely practiced. This observational study uses the ALBA test, a brief cognitive screening tool performed during the pre-anesthetic assessment, to predict the risk of POD, which will be assessed using the CAM-ICU tool for up to 72 hours after surgery. The study also examines how frailty, multiple medications, other health conditions, type of anesthesia, blood loss, medication during surgery, and postoperative complications relate to delirium. About 300-400 participants will be enrolled across seven centers, with no additional tests or changes to their standard care. Participants will undergo routine clinical care with cognitive screening before surgery and delirium monitoring after surgery. Data will be collected in an electronic system and analyzed to evaluate how well the ALBA test predicts delirium and to explore how feasible it is to include this screening in regular practice. The main outcome is the incidence of delirium within 72 hours after surgery, along with multiple secondary measures such as frailty, medication use, anemia, anesthesia type, and postoperative events. The study aims to improve preoperative evaluation and patient outcomes without adding extra procedures or biological sampling.